Showing 2,455 news articles about HIV treatment

Filters Content type: Editors' picks Topic: HIV treatment

Treatment is recommended for all people living with HIV. It involves taking a combination of antiretroviral drugs. This stops the virus from replicating and allows the immune system to strengthen and fight infections.

Access to healthcare

HIV patients in India protest shortage of drugs

Editor's pick
Deutsche Welle
10 August 2022
Injectable & long-acting HIV treatment

Long-Acting Injectable HIV Therapy for People Who Won’t Take ART?

Editor's pick
NEJM Journal Watch
10 August 2022
Treatment outcomes & life expectancy

Immune Recovery, Integrase Inhibitors Improve Survival for People With Late HIV Diagnosis

Editor's pick
POZ
9 August 2022
Child developmental issues

Differences in Early Growth Small for ART-Conceived Infants

Editor's pick
HealthDay News
9 August 2022
Treatment outcomes & life expectancy

Biktarvy Shows Durable Viral Suppression After 5 Years

Editor's pick
Infectious Disease Special Edition
5 August 2022
Weight gain & lipodystrophy

Switching From Integrase Inhibitor to PI Trims Weight in HIV Patient Database

Editor's pick
NATAP
5 August 2022
Treatment simplification strategies

Macrophage Activation for 2 Years After Switch From 3 to 2 Antiretrovirals

Editor's pick
NATAP
5 August 2022
Mental & emotional health & wellbeing

Lonely People With HIV Are More Likely to Skip Treatment

Editor's pick
POZ
3 August 2022
HIV treatment

Dolutegravir Around the World: Outcomes in Advanced AIDS and Maintenance Therapy

Editor's pick
TheBodyPro
2 August 2022
Support issues for children & young people

“Your status cannot hinder you”: A report on resilience among adolescents engaged in HIV care in Kenya

Editor's pick
Be In The Know
2 August 2022
Coronavirus

HIV Virologic Suppression Rates Before vs During the COVID-19 Pandemic

Editor's pick
Infectious Disease Advisor
2 August 2022
Resistance

Fostemavir Improves Outcomes for Treatment-Resistant HIV Patients

Editor's pick
Contagion Live
1 August 2022
HIV treatment

Mozambique: Half a Million HIV-Positive People Abandon Anti-Retroviral Treatment

Editor's pick
AllAfrica
29 July 2022
New & experimental HIV treatments

Gilead Sciences Statement on FDA Acceptance of New Drug Application for Investigational Lenacapavir

Editor's pick
Gilead Sciences press release
28 July 2022
Adherence

Motivational Interviewing May Increase Antiretroviral Therapy Adherence in Patients With HIV

Editor's pick
Infectious Disease Advisor
22 July 2022
PrEP

PrEP State of the Union: Adherence, Access, Uptake Issues

Editor's pick
Contagion Live
22 July 2022
Treatment outcomes & life expectancy

Risk of Mortality Similar Between Most First-Line Antiretroviral Regimens for HIV

Editor's pick
Infectious Disease Advisor
11 July 2022
The search for a cure

People Who Start HIV Treatment With High CD4s Have a Smaller Viral Reservoir

Editor's pick
POZ
7 July 2022
New & experimental HIV treatments

Fostemsavir Plus Optimized Background Therapy May Be Viable for Multidrug-Resistant HIV

Editor's pick
Infectious Disease Advisor
30 June 2022
New & experimental HIV treatments

Gilead Resubmits New Drug Application to U.S. Food and Drug Administration for Lenacapavir, an Investigational, Long-Acting HIV-1 Capsid Inhibitor

Editor's pick
Gilead Sciences press release
28 June 2022
Injectable & long-acting HIV treatment

Investigational Lenacapavir Receives Positive CHMP Opinion for People With Multi-Drug Resistant HIV

Editor's pick
Gilead Sciences press release
25 June 2022
New & experimental HIV treatments

Exavir Therapeutics announces publication of preclinical data for ultra-long-acting dolutegravir prodrug XVIR-120

Editor's pick
GlobeNewswire (press release)
13 June 2022
The search for a cure

Combination Anti-HIV Antibody Infusions Suppress Virus for Sustained Period

Editor's pick
HIV.gov
6 June 2022
Treatment guidelines

South Africa: Over 3 million people on new HIV drug, but not all smooth sailing

Editor's pick
Spotlight
1 June 2022